tiprankstipranks
Trending News
More News >
Kaken Pharmaceutical Co Ltd (JP:4521)
:4521

Kaken Pharmaceutical Co (4521) Price & Analysis

Compare
0 Followers

4521 Stock Chart & Stats

¥3712.00
-¥98.00(-2.16%)
At close: 4:00 PM EST
¥3712.00
-¥98.00(-2.16%)

Bulls Say, Bears Say

Bulls Say
Strong Balance SheetExceptionally low leverage and a high equity ratio provide durable financial flexibility. This supports continued R&D funding, selective M&A or partnerships, and resilience to reimbursement shocks from Japan’s NHI system. A strong balance sheet reduces refinancing and liquidity risk over the medium term.
High Profitability And MarginsElevated gross and operating margins indicate a defensible specialty-pharma franchise with pricing power and efficient operations. Sustainable margins generate internal cash for pipeline investment and shareholder returns, and provide a buffer versus pricing or volume shocks in core therapeutic areas.
Strong Cash GenerationSolid cash conversion and an increase in free cash flow enhance the company’s ability to self-fund development, pay dividends, and absorb temporary revenue setbacks. Reliable cash generation combined with low debt supports long-term strategic initiatives without immediate external financing.
Bears Say
Recent Revenue And Earnings DeclineMaterial year-on-year declines in revenue and EPS signal structural headwinds or product-cycle downturns that can persist. Reduced top-line and earnings compress internal investment capacity and raise execution risk for launches or commercialization, making medium-term forecasting and budgeting harder.
Concentration In Japan & NHI Pricing RiskHeavy reliance on Japan and exposure to periodic NHI price revisions creates recurring policy-driven revenue and margin risk. Limited geographic diversification magnifies the impact of reimbursement cuts or regulatory changes, constraining long-term revenue stability and growth optionality.
Cash Flow VolatilityVariability in free cash flow complicates capital allocation and may force trade-offs between R&D, dividends, and capital expenditures. Volatile cash conversion reflects sensitivity to product sales timing or one-offs, reducing predictability of funding for multi-year development programs.

4521 FAQ

What was Kaken Pharmaceutical Co Ltd’s price range in the past 12 months?
Kaken Pharmaceutical Co Ltd lowest stock price was ¥3540.00 and its highest was ¥4901.00 in the past 12 months.
    What is Kaken Pharmaceutical Co Ltd’s market cap?
    Kaken Pharmaceutical Co Ltd’s market cap is ¥153.08B.
      When is Kaken Pharmaceutical Co Ltd’s upcoming earnings report date?
      Kaken Pharmaceutical Co Ltd’s upcoming earnings report date is May 13, 2026 which is in 80 days.
        How were Kaken Pharmaceutical Co Ltd’s earnings last quarter?
        Kaken Pharmaceutical Co Ltd released its earnings results on Feb 06, 2026. The company reported ¥10.71 earnings per share for the quarter, missing the consensus estimate of ¥24.791 by -¥14.081.
          Is Kaken Pharmaceutical Co Ltd overvalued?
          According to Wall Street analysts Kaken Pharmaceutical Co Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Kaken Pharmaceutical Co Ltd pay dividends?
            Kaken Pharmaceutical Co Ltd pays a Semiannually dividend of ¥95 which represents an annual dividend yield of 4.16%. See more information on Kaken Pharmaceutical Co Ltd dividends here
              What is Kaken Pharmaceutical Co Ltd’s EPS estimate?
              Kaken Pharmaceutical Co Ltd’s EPS estimate is 47.07.
                How many shares outstanding does Kaken Pharmaceutical Co Ltd have?
                Kaken Pharmaceutical Co Ltd has 44,139,730 shares outstanding.
                  What happened to Kaken Pharmaceutical Co Ltd’s price movement after its last earnings report?
                  Kaken Pharmaceutical Co Ltd reported an EPS of ¥10.71 in its last earnings report, missing expectations of ¥24.791. Following the earnings report the stock price went down -0.121%.
                    Which hedge fund is a major shareholder of Kaken Pharmaceutical Co Ltd?
                    Currently, no hedge funds are holding shares in JP:4521
                    What is the TipRanks Smart Score and how is it calculated?
                    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                      Company Description

                      Kaken Pharmaceutical Co Ltd

                      Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

                      Kaken Pharmaceutical Co (4521) Earnings & Revenues

                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Kissei Pharmaceutical Co
                      Towa Pharmaceutical Co
                      Mochida Pharmaceutical Co., Ltd.
                      KYORIN Pharmaceutical Co.,Ltd.
                      SAWAI GROUP HOLDINGS Co., Ltd.

                      Options Prices

                      Currently, No data available
                      ---
                      Popular Stocks